100
Participants
Start Date
August 11, 2023
Primary Completion Date
June 16, 2025
Study Completion Date
May 30, 2027
Durvalumab
Participants will receive Durvalumab via intravenous infusion from Week 1 for 13 cycles every 4 weeks (q4w) for maximum 12 months.
BCG
Participants will receive BCG via intravesical as induction weekly for 6 weeks starting at Week 1, Day 1 and subsequently for maintenance for 3 weekly doses up to 3, 6, 12, 18, and 24 months, at the physician's discretion as Standard of care.
Research Site, Syracuse
Research Site, Hanover
Research Site, Baltimore
Research Site, Myrtle Beach
Research Site, Jacksonville
Research Site, Hialeah
Research Site, Nashville
Research Site, Cincinnati
Research Site, Greenwood
Research Site, Royal Oak
Research Site, Troy
Research Site, Wichita
Research Site, Little Rock
Research Site, Austin
Research Site, Lakewood
Research Site, Phoenix
Research Site, San Diego
Research Site, Spokane
Research Site, Bala-Cynwyd
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
AstraZeneca
INDUSTRY